Trials / Terminated
TerminatedNCT04373369
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether adding vorolanib to atezolizumab will improve the length of time that participants are cancer-free after receiving standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorolanib | Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle. |
| DRUG | Atezolizumab | Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle. |
Timeline
- Start date
- 2020-10-07
- Primary completion
- 2022-08-18
- Completion
- 2025-08-11
- First posted
- 2020-05-04
- Last updated
- 2025-11-03
- Results posted
- 2023-06-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04373369. Inclusion in this directory is not an endorsement.